Saptalis Pharmaceuticals LLC has announced the commercial launch of Cyclosporine Ophthalmic Emulsion 0.05%, further expanding its portfolio of prescription medicines in the United States.
The product is available in 30-count and 60-count single-use vials and is designed to help patients living with dry eye disease, a condition that affects millions of people worldwide. The preservative-free formulation is indicated to increase tear production in patients whose tear production may be reduced due to inflammation associated with dry eye disease.
With its single-use packaging and preservative-free design, the treatment offers patients a convenient option for managing inflammation-related tear deficiency.
Dry eye disease remains one of the most common eye conditions seen in clinical practice. Patients often experience symptoms such as irritation, burning, redness, blurred vision, and discomfort that can affect daily activities.
Cyclosporine Ophthalmic Emulsion 0.05% works by helping reduce inflammation that may interfere with normal tear production, supporting improved eye lubrication over time.
The launch reflects Saptalis' continued efforts to provide accessible treatment options for patients requiring long-term management of chronic eye conditions.
Alongside the launch of Cyclosporine Ophthalmic Emulsion, Saptalis announced the approval and commercial availability of several additional products covering a wide range of therapeutic categories.
Saptalis has launched Tofacitinib Oral Solution, 1 mg/mL, supplied in a 240 mL bottle.
The medication is indicated for the treatment of autoimmune and inflammatory disorders, including rheumatoid arthritis and other related conditions. The oral liquid formulation may offer an alternative administration option for patients who have difficulty swallowing tablets.
Hydroxyzine HCl Oral Solution Added to Portfolio
The company also introduced Hydroxyzine HCl Oral Solution USP 10 mg/5 mL in a 473 mL presentation.
Hydroxyzine is commonly prescribed for the relief of anxiety and tension. It is also used to manage itching and discomfort associated with allergic conditions.
Chlorpromazine Oral Concentrate Launches in Two Strengths
Saptalis announced the launch of Chlorpromazine HCl Oral Concentrate in two dosage strengths:
The medication is indicated for the treatment of schizophrenia and other psychotic disorders. It is also used for the management of severe nausea and vomiting in certain patients.
New Dermatology Products Enter the Market
The company expanded its dermatology portfolio with the launch of Desoximetasone Cream USP in two strengths:
The cream is available in both 15-gram and 60-gram package sizes and is used to relieve inflammation and itching associated with corticosteroid-responsive skin conditions.
Saptalis also launched Fluocinonide Topical Solution USP 0.05%, available in 20 mL and 60 mL bottles.
This topical treatment is indicated for inflammatory and itchy scalp and skin conditions that respond to corticosteroid therapy.
Company Focuses on Expanding Generic Medicines Business
According to Polireddy Dondeti, President and Chief Executive Officer of Saptalis Pharmaceuticals, these launches support the company's ongoing growth strategy in the generic pharmaceutical market.
He stated that Saptalis continues to expand its generic business segment through U.S.-based manufacturing operations while maintaining its focus on developing innovative branded therapies that address unmet medical needs.
The company sees these new product introductions as an important step in strengthening its position across multiple therapeutic categories.
Strengthening Presence in Liquid and Semi-Solid Dosage Forms
The newly launched products further expand Saptalis' portfolio of liquid and semi-solid dosage forms.
The company now has a broader presence in several key healthcare areas, including:
This diversified portfolio allows Saptalis to serve a wider range of patient and healthcare provider needs through specialized dosage forms.
All Products Available by Prescription
Saptalis confirmed that all newly launched products are available by prescription and should be used under the supervision of a licensed healthcare professional.
Healthcare providers can access detailed prescribing information through the company's official channels before making treatment decisions for patients.
About Saptalis Pharmaceuticals
Saptalis Pharmaceuticals LLC is a specialty pharmaceutical company focused on the research, development, manufacturing, and commercialization of generic and specialty branded medicines.
Headquartered in Hauppauge, New York, the company specializes in liquid and semi-solid dosage forms. Saptalis operates research and development laboratories as well as a commercial manufacturing facility that complies with U.S. FDA current Good Manufacturing Practice (cGMP) standards.
The company continues to invest in product development and manufacturing capabilities to support the growing demand for high-quality pharmaceutical treatments across multiple therapeutic areas.